Journal
CELL
Volume 184, Issue 21, Pages 5405-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2021.09.011
Keywords
-
Categories
Funding
- Steven and Alexandra Cohen Foundation
- Global Lyme Alliance
- NIH [R01AI122286, RO1AI132836]
Ask authors/readers for more resources
The research found that Hygromycin A can selectively eliminate B. burgdorferi, curing infections in mice, and causing less disruption to the host microbiome.
Lyme disease is on the rise. Caused by a spirochete Borreliella burgdorferi, it affects an estimated 500,000 people in the United States alone. The antibiotics currently used to treat Lyme disease are broad spectrum, damage the microbiome, and select for resistance in non-target bacteria. We therefore sought to identify a compound acting selectively against B. burgdorferi. A screen of soil micro-organisms revealed a compound highly selective against spirochetes, including B. burgdorferi. Unexpectedly, this compound was determined to be hygromycin A, a known antimicrobial produced by Streptomyces hygroscopicus. Hygromycin A targets the ribosomes and is taken up by B. burgdorferi, explaining its selectivity. Hygromycin A cleared the B. burgdorferi infection in mice, including animals that ingested the compound in a bait, and was less disruptive to the fecal microbiome than clinically relevant antibiotics. This selective antibiotic holds the promise of providing a better therapeutic for Lyme disease and eradicating it in the environment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available